Het Ziekenhuisnetwerk Antwerpen
- Address
- Lange Beeldekensstraat 267, 2060 Antwerp, Belgium
Cardiovascular Disease Research
At Het Ziekenhuisnetwerk Antwerpen, investigators are exploring innovative strategies to improve outcomes for patients with heart‑related conditions, focusing on preventing events such as heart attacks and strokes.
- Coronary artery disease
- Non‑ST‑segment elevation acute coronary syndrome
- Atrial fibrillation
- Prevention of stroke or systemic embolism
- Patients undergoing percutaneous coronary intervention
The work emphasizes the balance between reducing clotting risk and minimizing bleeding complications while enhancing long‑term survival.
Hematology and Oncology Research
The site conducts studies aimed at advancing treatment options for blood cancers and solid tumors, evaluating new agents that may extend survival and improve quality of life.
- B‑Cell Non‑Hodgkin's Lymphoma
- Diffuse Large B‑Cell Lymphoma
- Relapsed/refractory multiple myeloma
- Amyloid light‑chain amyloidosis
- Metastatic non‑small cell lung cancer
- Unresectable pleural mesothelioma
- Patients with resected colon carcinoma
Researchers collaborate across specialties to integrate novel therapies with established regimens, seeking measurable gains in progression‑free and overall survival.
Respiratory and Fibrotic Lung Disease Research
Clinical investigations at the hospital target chronic lung conditions, testing inhaled medicines and other interventions designed to slow disease progression and enhance breathing capacity.
- Fibrotic lung disease
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Unresectable pleural mesothelioma
- Metastatic non‑small cell lung cancer (lung focus)
Long‑term safety and tolerability remain central outcomes, with patient‑reported symptom relief being closely monitored.
Metabolic and Diabetes Prevention Research
Studies focus on early metabolic disturbances, aiming to prevent the onset of type 2 diabetes through lifestyle‑aligned pharmacologic approaches.
- Prediabetes
- Women with prior gestational diabetes
- Glucose intolerance
- Metabolic syndrome
The trials assess changes in fasting glucose, oral glucose tolerance, and HbA1c to determine the effectiveness of preventive therapy.
Diagnostic and Therapeutic Techniques Research
The institution also evaluates cutting‑edge equipment and procedures that support accurate diagnosis and targeted therapy across multiple disease areas.
- Advanced imaging for cardiovascular assessment
- Biomarker testing for hematologic malignancies
- Novel delivery systems for inhaled drugs
- Laboratory assays for amyloid detection
By integrating these technologies, the site strives to personalize care and streamline treatment pathways for its diverse patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 55 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 54 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1AstraZeneca AB1active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Het Ziekenhuisnetwerk Antwerpen
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4) | Regeneron Pharmaceuticals Inc. | Phase III | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 55 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 4 | Unknown | 2023-06-23 | 2024-06-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.